Clinical Trial: TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma

U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07639879) titled 'TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma' on May 26.

Brief Summary: This is a randomized, open-label, multicenter Phase III study evaluating the efficacy and safety of TR115, an EZH2 inhibitor, versus investigator's choice (chidamide, golidocitinib, mitoxantrone liposome, or gemcitabine) in patients with relapsed and/or refractory peripheral T/NK-cell lymphoma. Approximately 180 patients will be randomized in a 1:1 ratio. The primary endpoint is progression-free survival (PFS) assessed by an Independent Review Committee (IRC). The key secondary endpoint is overall survival (OS). The study i...